Kit signaling inhibits the sphingomyelin-ceramide pathway through PLC gamma 1: implication in stem cell factor radioprotective effect.

Cancer treatment strategies targeting sphingolipid metabolism. Adv Exp Med Biol (2010) 1.09

c-Kit-mediated overlapping and unique functional and biochemical outcomes via diverse signaling pathways. Mol Cell Biol (2004) 0.98

Roles and regulation of neutral sphingomyelinase-2 in cellular and pathological processes. Adv Biol Regul (2014) 0.85

Role of intracellular tyrosines in activating KIT-induced myeloproliferative disease. Leukemia (2012) 0.81

Modifying radiation damage. Curr Drug Targets (2010) 0.81

The effect of imatinib mesylate on the proliferation, invasive ability, and radiosensitivity of retinoblastoma cell lines. Eye (Lond) (2012) 0.79

KIT associated intracellular tyrosines play an essential role in EpoR co-signaling. Cell Signal (2008) 0.77

Label-free Quantitative Analysis of Changes in Broiler Liver Proteins under Heat Stress using SWATH-MS Technology. Sci Rep (2015) 0.76

Mutation in TET2 in myeloid cancers. N Engl J Med (2009) 16.07

TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell (2011) 5.28

ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med (2005) 4.13

Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J Biol Chem (2004) 3.64

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet (2011) 3.21

Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation (2007) 3.04

Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol (2009) 2.94

Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res (2011) 2.85

Role of Mre11 in chromosomal nonhomologous end joining in mammalian cells. Nat Struct Mol Biol (2009) 2.64

Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. J Clin Oncol (2012) 2.56

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood (2008) 2.39

Defects in XRCC4 and KU80 differentially affect the joining of distal nonhomologous ends. Proc Natl Acad Sci U S A (2007) 2.27

Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation (2008) 2.06

Antileukemic activity of rapamycin in acute myeloid leukemia. Blood (2004) 2.03

DNAM-1 and PVR regulate monocyte migration through endothelial junctions. J Exp Med (2004) 1.96

Improved survival of patients undergoing palliation of hypoplastic left heart syndrome: lessons learned from 115 consecutive patients. Circulation (2002) 1.95

Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood (2011) 1.87

Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis. J Natl Cancer Inst (2006) 1.80

Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood (2004) 1.78

DNA-dependent protein kinase and XRCC4-DNA ligase IV mobilization in the cell in response to DNA double strand breaks. J Biol Chem (2004) 1.72

Syk-dependent mTOR activation in follicular lymphoma cells. Blood (2006) 1.68

Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol (2013) 1.65

The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene (2005) 1.64

Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis. J Clin Oncol (2009) 1.64

Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study. Blood (2011) 1.62

International Society for Heart and Lung Transplantation: Practice guidelines for management of heart failure in children. J Heart Lung Transplant (2004) 1.59

Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res (2013) 1.58

Preventing pediatric sudden cardiac death: where do we start? Pediatrics (2006) 1.58

Cell nonhomologous end joining capacity controls SAF-A phosphorylation by DNA-PK in response to DNA double-strand breaks inducers. Cell Cycle (2009) 1.57

Prominent role of the Ig-like V domain in trans-interactions of nectins. Nectin3 and nectin 4 bind to the predicted C-C'-C"-D beta-strands of the nectin1 V domain. J Biol Chem (2002) 1.54

What lessons can be learned from γδ T cell-based cancer immunotherapy trials? Cell Mol Immunol (2012) 1.54

TRF2 and apollo cooperate with topoisomerase 2alpha to protect human telomeres from replicative damage. Cell (2010) 1.50

Coordinated assembly of Ku and p460 subunits of the DNA-dependent protein kinase on DNA ends is necessary for XRCC4-ligase IV recruitment. J Mol Biol (2003) 1.48

The cell cycle regulator CDC25A is a target for JAK2V617F oncogene. Blood (2011) 1.47

Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood (2009) 1.47

Response to cardiac arrest and selected life-threatening medical emergencies: the medical emergency response plan for schools: A statement for healthcare providers, policymakers, school administrators, and community leaders. Circulation (2004) 1.45

Structural and functional interaction between the human DNA repair proteins DNA ligase IV and XRCC4. Mol Cell Biol (2009) 1.43

Mast cell leukemia. Blood (2012) 1.42

Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res (2004) 1.42

SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias. Leuk Lymphoma (2012) 1.39

Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis. Cancer Res (2004) 1.38

Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM-17. J Biol Chem (2005) 1.34

Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors. Mol Cancer Res (2008) 1.31

Nectin-4 is a new histological and serological tumor associated marker for breast cancer. BMC Cancer (2007) 1.30

The tumor suppressor activity of SOCS-1. Oncogene (2002) 1.29

Danon disease as an underrecognized cause of hypertrophic cardiomyopathy in children. Circulation (2005) 1.24

Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies. Blood (2009) 1.24

Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene (2003) 1.23

Interplay between Ku, Artemis, and the DNA-dependent protein kinase catalytic subunit at DNA ends. J Biol Chem (2006) 1.21

The loss of gammaH2AX signal is a marker of DNA double strand breaks repair only at low levels of DNA damage. Cell Cycle (2006) 1.21

Signal transduction by several KIT juxtamembrane domain mutations. Oncogene (2003) 1.20

Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene (2004) 1.19

Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation. J Exp Med (2005) 1.18

The membrane form of the DNA repair protein Ku interacts at the cell surface with metalloproteinase 9. EMBO J (2004) 1.18

Involvement of polynucleotide kinase in a poly(ADP-ribose) polymerase-1-dependent DNA double-strand breaks rejoining pathway. J Mol Biol (2005) 1.18

Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells. Cancer Res (2013) 1.16

Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood (2004) 1.14

UV-C light induces raft-associated acid sphingomyelinase and JNK activation and translocation independently on a nuclear signal. J Biol Chem (2005) 1.13

The double life of the Ku protein: facing the DNA breaks and the extracellular environment. Cell Cycle (2005) 1.13

A G-quadruplex structure within the 5'-UTR of TRF2 mRNA represses translation in human cells. Nucleic Acids Res (2010) 1.13

Rituximab inhibits B-cell receptor signaling. Blood (2009) 1.13

Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathway. Blood (2005) 1.12

Ku counteracts mobilization of PARP1 and MRN in chromatin damaged with DNA double-strand breaks. Nucleic Acids Res (2011) 1.12

The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. Oral Oncol (2007) 1.11

A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol (2014) 1.11

TRF2/RAP1 and DNA-PK mediate a double protection against joining at telomeric ends. EMBO J (2010) 1.11

Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. Thyroid (2008) 1.10

In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells. Blood (2012) 1.10

Transcriptional activators stimulate DNA repair. Mol Cell (2002) 1.10

Interplay between Cernunnos-XLF and nonhomologous end-joining proteins at DNA ends in the cell. J Biol Chem (2007) 1.09

Case-control cohort study of patients' perceptions of disability in mastocytosis. PLoS One (2008) 1.07

Mixed venous oxygen saturation monitoring after stage 1 palliation for hypoplastic left heart syndrome. Ann Thorac Surg (2007) 1.07

PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma. Blood (2007) 1.06

Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study. Arthritis Res Ther (2009) 1.05

Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model. PLoS One (2010) 1.05

Tumor necrosis factor-alpha inhibits hTERT gene expression in human myeloid normal and leukemic cells. Blood (2005) 1.05

Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. Blood (2013) 1.04

Effect of double-strand break DNA sequence on the PARP-1 NHEJ pathway. Biochem Biophys Res Commun (2007) 1.04

Flow cytometric measurement of calpain activity in living cells. Cytometry A (2007) 1.02

Long-patch DNA repair synthesis during base excision repair in mammalian cells. EMBO Rep (2003) 1.02

Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation. Breast Cancer Res Treat (2007) 1.02

The Membrane-associated form of the DNA repair protein Ku is involved in cell adhesion to fibronectin. J Mol Biol (2004) 1.02

Tumor necrosis factor alpha induces senescence and chromosomal instability in human leukemic cells. Oncogene (2004) 1.02

Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice. Cancer Cell (2005) 1.01

BRCA1-Ku80 protein interaction enhances end-joining fidelity of chromosomal double-strand breaks in the G1 phase of the cell cycle. J Biol Chem (2013) 1.01

Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol (2010) 1.01

Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells. Blood (2006) 0.99

Suppressor of cytokine signaling 6 associates with KIT and regulates KIT receptor signaling. J Biol Chem (2004) 0.99

Cancer-associated adipocytes promotes breast tumor radioresistance. Biochem Biophys Res Commun (2011) 0.99

Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. Blood (2014) 0.98

Phenotypic and genotypic characteristics of mastocytosis according to the age of onset. PLoS One (2008) 0.98

Sphingolipids as modulators of cancer cell death: potential therapeutic targets. Biochim Biophys Acta (2006) 0.98

The E3 ubiquitin ligase HOIL-1 induces the polyubiquitination and degradation of SOCS6 associated proteins. FEBS Lett (2006) 0.98

Ionizing-radiation induced DNA double-strand breaks: a direct and indirect lighting up. Radiother Oncol (2013) 0.97

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study. BMC Neurol (2012) 0.97

Role of the proteasome in the regulation of estrogen receptor alpha turnover and function in MCF-7 breast carcinoma cells. J Steroid Biochem Mol Biol (2005) 0.96

p210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation. Blood (2003) 0.96